Dosage and duration of the treatment:
Always use this medicine exactly as your doctor has told you. Check with your doctor if you are not sure.
Women who are not ovulating and are having irregular periods or no periods at all:
As a general rule, 75 to 150 IU of FSH is given per day during the first week of the cycle after spontaneous or induced menses. Your physician will increase the meriofert dosage, by 37.5 IU (up to 75 IU), depending on the ovarian response which is determined by clinical examinations.
Treatment will continue until one or more ripe follicle have developed in the ovary.
As soon as one follicle reaches the required development stage, the Meriofert treatment will be withheld and ovulation will be triggered with another hormone (chorionic gonadotropin, hCG).
Ovulation generally takes place after 32 to 48 hours.
In this phase of the treatment, fertilization is possible. You will be advised to have sexual intercourse every day starting from the day preceding the administration of hCG. If pregnancy is not achieved in spite of ovulation, the treatment can be repeated.
Women undergoing ovarian stimulation for multiple follicular development prior to in vitro fertilisation or other assisted reproductive techniques:
The aim of this method is to obtain concomitant multiple follicular development. The treatment will start on the 2nd or 3rd day of the cycle with injections of 150-300 IU of Meriofert. Your physician may decide to administer higher dosages if required. The injected dosage of Meriofert is higher than in the method used for natural fertilization. The continuation of the treatment is adjusted individually by the physician.
As soon as a sufficient number of follicles has developed, the treatment with Meriofert is withheld and ovulation is triggered by injecting another hormone (chorionic gonadotropin, hCG).
How Meriofert should be given:
Meriofert is given by injection under your skin (by the subcutaneous route) or into your muscle (intramuscular injection).
The injection should be performed slowly to prevent pain and backflow of product at the injection site. The injection site should be alternated to prevent lipoatrophy.
As this vial contains medication for several days of treatment, 12 administration syringes graduated in FSH/LH IU units are provided to draw up the correct single dose of MERIOFERT 900 IU (international units). MERIOFERT 900 IU may be recommended for patient self-administration.
After suitable advice and training your doctor may ask you to inject Meriofert yourself.
For the first time, your doctor must:
- Let you practise giving yourself a subcutaneous injection,
- Have shown you the possible places where you can inject yourself,
- Have shown you how to prepare the solution for injection,
- Have explained how to prepare the right dose of injection.
Before injecting Meriofert yourself, read the following instructions carefully.
How to prepare and inject Meriofert 900 IU:
Each vial is for multiple use.
The powder must be reconstituted immediately before the first injection under aseptic conditions. Meriofert must only be reconstituted with the solvent provided in the package.
Prepare a clean surface and wash your hands before the solution is reconstituted. It is important that your hands and the items you use are as clean as possible.
Set out all the following items on the clean surface:
- One vial containing Meriofert powder,
- One prefilled syringe with the solvent
- One needle for reconstitution
- One needle for preparing the injection (not provided),
- 1 alcohol swab;
- 1 disposable syringe for subcutaneous administration graduated in FSH/LH units.
